Open access
Open access
Powered by Google Translator Translator

Family Medicine

The study behind new CDC’s mask guidance found vaccinated people can spread delta variant.

2 Aug, 2021 | 00:33h | UTC

CDC Report: Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 – Centers for Disease Control and Prevention

Commentaries:

The Study Behind CDC’s Mask Guidance Found Vaccinated People Can Spread Delta Variant – NPR

What Delta has changed in the Covid pandemic — and what it hasn’t – STAT

 

Commentary on Twitter (thread – click for more)

 


ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

2 Aug, 2021 | 00:31h | UTC

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM)

Additional reading:

Practice Advisory: COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care

COVID-19 Vaccines and Pregnancy: Conversation Guide for Clinicians

Commentaries:

Obstetrician groups recommend COVID vaccine during pregnancy – Associated Press

Statements By Obstetrics Societies Strongly Advise Covid-19 Vaccinations For Pregnant Women – Forbes

 

Commentary on Twitter

 


Post-viral effects of COVID-19 in the olfactory system and their implications.

2 Aug, 2021 | 00:24h | UTC

Post-viral effects of COVID-19 in the olfactory system and their implications – The Lancet Neurology

Related:

Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.

Eight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).

Loss of smell in mild Covid-19 cases occurs 86% of the time, study says

Management of anosmia and loss of smell in the era of Covid-19

 


Ten things to know about ten imaging studies: A preventive cardiology perspective.

2 Aug, 2021 | 00:12h | UTC

Ten things to know about ten imaging studies: A preventive cardiology perspective (“ASPC top ten imaging”) – American Journal of Preventive Cardiology

 


AHA Scientific Statement: Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions.

2 Aug, 2021 | 00:17h | UTC

Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association – Circulation

Top Things to Know: Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions – American Heart Association

Commentary: The Need for Improved Identification and Treatment of Peripheral Arterial Disease – American Heart Association

 


Assessment and management of peripheral arterial disease: what every cardiologist should know.

2 Aug, 2021 | 00:15h | UTC

Assessment and management of peripheral arterial disease: what every cardiologist should know – Heart

 

Commentary on Twitter

https://twitter.com/Heart_BMJ/status/1417391335246553094

 


Ten things to know about ten cardiovascular disease risk factors.

2 Aug, 2021 | 00:11h | UTC

Ten things to know about ten cardiovascular disease risk factors – American Journal of Preventive Cardiology

 


Study: many patients with small renal masses can be safely managed with active surveillance.

2 Aug, 2021 | 00:07h | UTC

Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention – The Journal of Urology

Commentary: More Data Support Active Surveillance for Small Renal Masses — Most patients avoided surgery with no metastasis, better focus on aggressive disease – MedPage Today (free registration required)

 


Guideline summary: A Multidisciplinary collaborative approach to retinal toxic effects screening for patients taking antimalarials.

2 Aug, 2021 | 00:03h | UTC

A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials – JAMA Dermatology (free for a limited period)

Original Guidance: Joint Statement: Hydroxychloroquine use with respect to retinal toxicity

 


Does this adult patient have hypertension? the rational clinical examination systematic review.

2 Aug, 2021 | 00:05h | UTC

Does This Adult Patient Have Hypertension? The Rational Clinical Examination Systematic Review – JAMA (free for a limited period)

 


Viewpoint: The road to addressing Long Covid.

30 Jul, 2021 | 12:09h | UTC

The road to addressing Long Covid – Science (a few articles per month are free)

Related: Review: Long covid—mechanisms, risk factors, and management.

 

Commentary on Twitter

 


NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

30 Jul, 2021 | 12:14h | UTC

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis – National Institute for Health and Care Excellence

News release: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence

Related: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 


Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

30 Jul, 2021 | 12:12h | UTC

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know – Blood

Related: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 


Study: Patients who have recovered from COVID-19 may have persistent cognitive symptoms.

30 Jul, 2021 | 12:03h | UTC

Cognitive deficits in people who have recovered from COVID-19 – EClinicalMedicine

 

Commentary on Twitter (thread – click for more)

 


Risk of acute myocardial infarction and ischemic stroke following COVID-19 in Sweden – “the true risk is increased by between three and eight times for acute myocardial infarction and by between three and seven times for ischaemic stroke following COVID-19.”

30 Jul, 2021 | 12:06h | UTC

Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study – The Lancet

Invited commentary: What is the association of COVID-19 with heart attacks and strokes? – The Lancet

 

Commentary on Twitter

 


Self-reported memory problems 8 months after COVID-19 infection.

30 Jul, 2021 | 12:02h | UTC

Self-reported Memory Problems 8 Months After COVID-19 Infection – JAMA Network Open

Commentary: Post-acute Sequelae of SARS-CoV-2 Infection and Subjective Memory Problems – JAMA Network Open

 

Commentary on Twitter (thread – click for more)

 


Israel to offer 3rd COVID booster shot to older citizens.

30 Jul, 2021 | 11:57h | UTC

Israel to offer 3rd COVID booster shot to older citizens – Associated Press

 


RCT: Among pregnant women with primary CMV infection diagnosed before 24 weeks’ gestation, monthly infusion of CMV hyperimmune globulin did not prevent congenital cytomegalovirus infection.

30 Jul, 2021 | 11:42h | UTC

A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Hyperimmune Globulin Fails to Prevent Congenital CMV – Physician’s Weekly

 


Serious complications from youth-onset type 2 diabetes arise by young adulthood.

30 Jul, 2021 | 11:47h | UTC

Commentary: Serious complications from youth-onset type 2 diabetes arise by young adulthood – NIH News Release

Original study: Long-Term Complications in Youth-Onset Type 2 Diabetes – New England Journal of Medicine

 

Commentary on Twitter

 


Review: Changing paradigms in the management of acute uncomplicated diverticulitis.

30 Jul, 2021 | 11:37h | UTC

Changing Paradigms in the Management of Acute Uncomplicated Diverticulitis – Scandinavian Journal of Surgery

Related:

RCT: Another study shows that non-antibiotic outpatient treatment in mild acute diverticulitis is safe.

Review: Elective surgical management of diverticulitis

State of the Art Review | Management of colonic diverticulitis

Drains, germs, or steel: Multidisciplinary management of acute colonic diverticulitis

Diverticulitis: Observational study in outpatients suggests amoxicillin-clavulanate is a safe and effective option compared with metronidazole-fluoroquinolone

Randomized trial: Laparoscopic lavage vs. primary resection for perforated purulent diverticulitis; similar long-term results, but recurrence was more common after laparoscopic lavage

Randomized trial: In patients with recurrent, complicated, or persistent painful diverticulitis, sigmoid resection improved quality of life but was associated with a small but significant risk of major complications

Systematic review: Management of colonic diverticulitis

WSES Guidelines for the Management of Acute Colonic Diverticulitis

ASCRS Guidelines for the Treatment of Left-Sided Colonic Diverticulitis

 

Commentary on Twitter

https://twitter.com/ScandJSurg/status/1420655333815427084

 


Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

29 Jul, 2021 | 11:38h | UTC

Ivermectin for preventing and treating COVID‐19 – Cochrane Library

Summary: Ivermectin for preventing and treating COVID-19 – Cochrane Library

Commentary: Ivermectin treatment in humans for COVID-19 – Liverpool School of Tropical Medicine

Related:

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 


PRINCIPLE RCT: Doxycycline does not improve outcomes in outpatients with suspected COVID-19 at high risk for adverse outcomes.

29 Jul, 2021 | 11:36h | UTC

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet Respiratory Medicine

Commentary: PRINCIPLE: a community-based COVID-19 platform trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

https://twitter.com/LancetRespirMed/status/1420302490864603142

 


What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination.

29 Jul, 2021 | 11:28h | UTC

What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination – The Conversation

 


2021 ACC expert consensus decision pathway for cardiovascular risk reduction in patients with persistent hypertriglyceridemia.

29 Jul, 2021 | 11:15h | UTC

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

Key points: ACC Consensus on ASCVD Risk Reduction in Hypertriglyceridemia – American College of Cardiology

 

Commentary on Twitter

 


Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show.

29 Jul, 2021 | 11:19h | UTC

Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show – STAT

Original study (preprint): Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine – medRxiv

 

Commentary on Twitter (thread – click for more)

https://twitter.com/hildabast/status/1420481872212070404

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.